Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

December 31, 2027

Study Completion Date

May 31, 2031

Conditions
Systemic Lupus ErythematosusSystemic Sclerosis
Interventions
BIOLOGICAL

Depletion of CD3/CD19 in an autologous stem cell transplant

The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Stephan Grupp MD PhD

OTHER